Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

Researchers from the German Cancer Research Center and the University of Freiburg show how certain painkillers influence the ...

HIF-2α inhibitors, like belzutifan, are emerging as promising second-line treatments for RCC, with ongoing trials showing ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

Cells are regularly faced with environmental stresses that may damage or destroy them. To survive, they quickly adjust their ...

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for ...